focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Not all mergers fall apart

Tue, 15th Sep 2020 10:33

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni
(danilo.masoni@thomsonreuters.com) and Stefano Rebaudo (stefano.rebaudo@thomsonreuters.com) in
Milan.

NOT ALL MERGERS FALL APART (0928 GMT)

Let's face it: completing merger deals has become more challenging in this new COVID-19
world.

Take LVMH/Tiffany in luxury and Fiat Chrysler/PSA in the automotive sector. Both deals were
bigly challenged by the turmoil created by the pandemic but while LVMH resolved to call off the
deal (with political interference playing crucial part in the decision), the merger to create
the world's No. 4 carmaker is nevertheless going ahead.

But that comes with a cost, which seems investors are willing to pay, and may raise further
hopes that M&A could recover after activity collapsed in the second quarter of 2020.

To preserve cash, FCA will nearly halved its pre-merger special dividend to 2.9 billion
euros and France's PSA will in turn postpone the planned spinoff of its 46% stake in parts maker
Faurecia until after the merger's closing.

The decision might have been a tough one to take but after all that will result in a
financially stronger group, which combined with sharp increase in the synergy target explains
why their shares reacted positively at the start of trading.

It looks that investors are looking beyond any short term gains, preferring synergies
tomorrow than dividends today.

"The higher value of the industrial synergies more than offset any revision of terms," says
Equita.

PSA shares hit a 6-month high before retreating to trade down 1% on the day, while FCA
shares are up 6%.

(Danilo Masoni)

*****

STOCK PRICES RANGEBOUND UP TO END 2020 (0910 GMT)

It won’t be all about virus trajectories and macro data for the stock market as there is a
lot going on, starting with the U.S. presidential elections.

After UBS yesterday said the stock market is fragile but it was confident that investors
will turn their focus on the positives soon, JP Morgan analysts sound even more cautious.

They line up risks that equities will face and say that the STOXX 600 index will remain
rangebound by end 2020.

This is in line with our Aug 26 poll which showed investors were on average expecting the
STOXX 600, currently at 370 points, to end the year at 375 points.

On the U.S, presidential election front, the real danger is the vote ending along the lines
of the Bush versus Gore Florida recount in 2000, leading to a ”legislative paralysis for some
time,” a JP Morgan research note says.

Foreign trade is going to be an issue whoever wins as “polls suggest that the unfavourable
views of China have become firmly bipartisan,” it adds.

Technicals are not helping as positioning is far from depressed, with “short interest and
put/call ratios at lows.”

Besides, fundamentals could soften if labour market improvement stalls and if the virus
dampens the recovery; default rates might spike; geopolitical risks are in place with “Brexit,
Russia, Iran and other.”

“We do not think that any of the above risks should necessarily be seen as a clear base
case, but the potential is that some of them might be realized.”

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: BIG MOVES UNDER THE FLAT SURFACE (0715 GMT)

European shares are off to a cautious start but under the flat surface there are some big
moves.

H&M is rallying 10% after its Q3 profit beat expectations, while in the auto sector
FCA is up 7% and PSA is gaining 1% after they revised the terms of their
merged in a bid to conserve cash. The revision meant that PSA will postpone the sale of its
stake in parts maker Faurecia, which is down 8.6%.

Strong retail sales are pushing online supermarket Ocado up 4.7%.

After initial gains at the open, the STOXX 600 has now pulled back, trading down
0.10%.

(Danilo Masoni)

*****

PSA/FCA, PAYMENTS DEALS, BANKS AND VACCINE NEWS ON OUR RADAR (0639 GMT)

While rangebound trading looks set to continue in typical pre-Fed fashion -- EUROSTOXX 50
futures are just flat -- on the corporate front some dealmaking headlines could liven up the
session, along with fresh vaccine updates.

PSA and Fiat Chrysler (FCA) have revised the terms of their planned
merger to conserve cash. FCA will cut to 2.9 billion euros the cash portion of a 5.5 billion
euro special dividend, while the French group will postpone to after the merger's closing the
planned spinoff of its 46% stake in parts maker Faurecia.

In the buoyant payments industry, Klarna Bank AB has raised $650 million at a valuation of
$10.65 billion from investors led by Silver Lake, while in Italy la Repubblica
reports that Nexi and smaller rival SIA are nearing a preliminary agreement for a
merger

In banks, one day after talk of a potential tie-up between Credit Suisse and UBS
, the focus may turn to Spain. A source said Caixabank is
considering a bid for Bankia that could value it at around 4 billion euros -- a
premium of between 15% and just above 20% over Bankia's average 3-month share price.

Vaccine news does not seem so bright today with sources saying AstraZeneca's
COVID-19 vaccine trial remains on hold in the United States pending a U.S. investigation into a
serious side effect in Britain even as other trials of the vaccine resume.

Shares in Zurich-lised Siegfried however rose 1.9% in premarket after a contract
with BioNTech to fill and pack a potential COVID-19 vaccine, while Lonza also gained
after unveiling a collaboration deal to expand the manufacturing of Humanigen's COVID-19
therapeutic candidate Lenzilumab.

Meantime in the UK, the pandemic generated huge demand for online deliveries, sending UK
online supermarket Ocado's retail sales in the 13 weeks to Aug. up 52%.

We'll also keep an eye on Daimler after courts documents showed it will pay $2.2
billion violating U.S. clean air laws and to resolve claims from 250,000 U.S. vehicle owners.

(Danilo Masoni)

*****

MORNING CALL: A CHOPPY DAY AHEAD? (0530 GMT)

European bourses look set for another choppy session today with futures moving between flat
and slightly lower, while spreabetters' calls are pointing to marginal gains.

The main event of this week is the Fed's two-day policy meeting which could help provide
fresh direction, while the German ZEW may draw some attention later today.

The day in Asia saw Chinese stocks rise following data that showed industrial output
expanded for a fifth straight month in August, while the Nikkei pulled back.

Meantime, U.S. futures rose slightly.

Futures for the S&P 500 were up 0.3%, while EUROSTOXX 50 futures eased 0.2%

(Danilo Masoni)

*****

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.